Cue Biopharma, Inc.
Business
Cue Biopharma is a clinical-stage biopharmaceutical company developing injectable therapeutics engineered to selectively modulate disease-specific T cells using its proprietary Immuno-STAT platform. The company's pipeline includes the CUE-400 series for autoimmune diseases, the CUE-500 series for targeted cell depletion, and the CUE-100 series for oncology, with lead candidate CUE-401 in preclinical development. Cue has established strategic collaborations with Boehringer Ingelheim for CUE-501 and ImmunoScape for the CUE-100 series, and holds exclusive licensed intellectual property from Albert Einstein College of Medicine covering its core T cell modulation technology platform.
Summary from 10-K filed 2026-03-16
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Collaboration revenue | 27 | 9 | 5 | 1 | 15 | |
| General and administrative | 16 | 15 | 17 | 16 | 17 | |
| Research and development | 38 | 36 | 41 | 39 | 41 | |
| Loss (gain) on fixed asset disposal | 31,000 | −93,000 | 157,000 | — | — | |
| Total operating expenses | 54 | 51 | 58 | 54 | 59 | |
| Loss from operations | −27 | −42 | −52 | −53 | −44 | |
| Interest income | 807,000 | 2 | 3 | 928,000 | 45,898 | |
| Interest expense | −357,000 | −796,000 | −1 | −713,000 | 0 | |
| Total other income, net | 450,000 | 826,000 | 1 | 215,000 | 45,898 | |
| Loss before provision for income taxes | −26 | −41 | — | — | — | |
| Provision for income taxes | −500,000 | 0 | — | 0 | −495,000 | |
| Net loss | −27 | −41 | −51 | −53 | −44 | |
| Net loss per common share - basic | −0.28 | −0.72 | −1.11 | −1.49 | −1.41 | |
| Net loss per common share - diluted | −0.28 | −0.72 | −1.11 | −1.49 | −1.41 | |
| Weighted average common shares outstanding, basic | 95 | 56 | 46 | 36 | 31 | |
| Weighted average common shares outstanding, diluted | 95 | 56 | 46 | 36 | 31 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 27 | 22 | 49 | 52 | 64 | |
| Accounts receivable | 6 | 945,000 | 2 | 57,000 | 3 | |
| Deposits, current portion | 1 | 929,000 | 287,000 | — | — | |
| Prepaid expenses and other current assets | 1 | 805,000 | 955,000 | 841,000 | 954,792 | |
| Foreign withholding tax receivable | 2 | 0 | — | — | — | |
| Total current assets | 37 | 25 | 51 | 77 | 68 | |
| Property and equipment, net | 241,000 | 471,000 | 795,000 | 1 | 2 | |
| Operating lease, right-of-use asset | 4 | 4 | 6 | 9 | 10 | |
| Deposits, net of current portion | 666,000 | 2 | 3 | 3 | 3 | |
| Restricted cash | 154,000 | 152,000 | 151,000 | 150,000 | 150,000 | |
| Other long term assets | 94,000 | 105,000 | 117,000 | 128,000 | 140,000 | |
| Total assets | 42 | 32 | 62 | 91 | 83 | |
| Accounts payable | 4 | 3 | 4 | 3 | 3 | |
| Accrued expenses | 2 | 3 | 4 | 4 | 5 | |
| Research and development contract liability, current portion | 5 | 85,000 | 2 | 0 | 645,344 | |
| Operating lease liabilities, net of current portion | 2 | 4 | 3 | 3 | 5 | |
| Current portion of long-term debt, net | 0 | 4 | 4 | 2 | 0 | |
| Other current payable | 689,000 | 0 | — | — | — | |
| Total current liabilities | 13 | 14 | 17 | 12 | 13 | |
| Operating lease liabilities, current portion | 2 | 1 | 3 | 6 | 5 | |
| Total liabilities | 16 | 15 | 24 | 26 | 18 | |
| Commitments and contingencies (Note 14) | — | — | — | — | — | |
| Preferred stock, $0.001 par value; 10,000,000 shares authorized and 0 shares issued and outstanding at December 31, 2025 and December 31, 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.001 par value; 300,000,000 and 200,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 96,621,218 and 61,819,101 shares issued and outstanding at December 31, 2025 and 2024, respectively | 97,000 | 62,000 | 47,000 | 43,000 | 32,202 | |
| Additional paid in capital | 395 | 359 | 338 | 316 | 263 | |
| Accumulated deficit | −368 | −342 | −301 | −250 | −197 | |
| Total stockholders equity | 26 | 17 | 37 | 66 | 65 | |
| Total liabilities and stockholders equity | 42 | 32 | 62 | 91 | 83 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −27 | −41 | −51 | −53 | −44 | |
| Depreciation and amortization | 958,000 | 397,000 | 556,000 | 922,000 | 1 | |
| Stock-based compensation | 5 | 7 | 8 | 9 | 12 | |
| Decrease in the carrying amount of right-of-use assets | 3 | 2 | 3 | 884,000 | — | |
| Amortization of premium/discount on purchased securities | −212,000 | 0 | −234,000 | −321,000 | −4,581 | |
| Amortization of debt issuance costs | 37,000 | 37,000 | 37,000 | 31,000 | 0 | |
| Accretion of final payment of term loan | 130,000 | 130,000 | 130,000 | 109,000 | 0 | |
| Accounts receivable | −5 | 753,000 | −2 | 3 | −2 | |
| Prepaid expenses and other current assets | −1 | 150,000 | −401,000 | 34,000 | −50,434 | |
| Deposits | 1 | 93,000 | 426,000 | −395,000 | −148,515 | |
| Foreign withholding tax receivable | −2 | 0 | — | — | — | |
| Other payable | 689,000 | 0 | — | — | — | |
| Accounts payable | 1 | −678,000 | 770,000 | 83,000 | 520,398 | |
| Accrued expenses | −1 | −1 | 588,000 | −1 | 2 | |
| Research and development contract liability, current portion | 5 | −2 | 2 | −645,000 | −8 | |
| Operating lease liability | −3 | −2 | −3 | −735,000 | 3 | |
| Net cash used in operating activities | −22 | −36 | −40 | −42 | −39 | |
| Purchases of property and equipment | −177,000 | −66,000 | 0 | −171,000 | −913,039 | |
| Cash received from the sale of property and equipment | 40,000 | 98,000 | 2,000 | 6,000 | 21,550 | |
| Purchases of marketable securities | −16 | 0 | — | — | — | |
| Redemption of marketable securities | 17 | 0 | 25 | 5 | 10 | |
| Net cash provided by investing activities | 75,000 | 32,000 | 25 | −25 | 9 | |
| Proceeds from ATM offering, net of sales agent commission and fees | 3 | 3 | 13 | 17 | 17 | |
| Proceeds from issuance of common stock, warrants and pre-funded warrants, net of transaction costs | 28 | 11 | 0 | 23 | 0 | |
| Repayment of term loans | −5 | −4 | −2 | 0 | — | |
| Issuance of common stock upon exercise of warrants and pre-funded warrants, net | 0 | 18,000 | 0 | 5 | 0 | |
| Net cash provided by financing activities | 26 | 10 | 12 | 54 | 19 | |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 5 | −26 | −3 | −13 | −10 | |
| Cash paid for interest | 214,000 | 669,000 | 1 | 570,000 | 0 | |
| Lease liabilities arising from obtaining right-of-use assets | 2 | 1 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Cue Biopharma, Inc.'s CIK number?
Cue Biopharma, Inc.'s SEC CIK number is 0001645460 (1645460). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Cue Biopharma, Inc.'s SEC filings?
All of Cue Biopharma, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Cue Biopharma, Inc. last report earnings?
Cue Biopharma, Inc. (CUE) most recently filed an earnings 8-K with the SEC on Mar 16, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-108292). This is Cue Biopharma, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Cue Biopharma, Inc.'s most recent earnings 8-K?
Cue Biopharma, Inc.'s latest earnings 8-K (Item 2.02) was filed Mar 16, 2026 under accession 0001193125-26-108292. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Cue Biopharma, Inc.'s latest earnings 8-K →
Look up any company's CIK number →